Core Insights - VIOMI Technology Co., Ltd. is positioning itself as a leader in smart water purification technology, emphasizing the importance of safe and high-quality drinking water for households during the holiday season [1][14] - The company is offering significant discounts on its water purifiers during Amazon's Black Friday event, with promotions running from November 20 to December 1, featuring discounts of up to 50% [2][14] Product Offerings - The flagship product, VIOMI MASTER M1, integrates a 9-stage filtration system with remineralization technology, significantly reducing reliance on bottled water and enhancing water quality [4][5] - The VORTEX V8 is designed for larger households, providing a high-capacity flow rate of 800 GPD and a 3:1 pure-to-drain ratio, which minimizes water waste [8][10] - The VORTEX V6 is positioned as a cost-effective option, certified to reduce up to 99.60% of PFOA/PFOS and 94.75% of TDS, making it accessible for small to medium-sized homes [12][13] Technological Features - The MASTER M1 features a smart touch-screen faucet that connects with the VIOMI App, providing real-time data on water quality and filter lifespan [6] - The VORTEX V8's tankless design saves space and prevents bacterial growth, ensuring fresh water availability [11] - All products utilize advanced filtration technology, with the MASTER M1 removing over 99% of harmful substances, and the VORTEX series maintaining high efficiency and long filter lifespans [5][11] Company Overview - VIOMI is committed to redefining modern homes with its mission of "AI for Better water," integrating artificial intelligence with advanced filtration systems [14] - The company operates one of the world's most advanced water purifier manufacturing facilities and holds a substantial portfolio of over 7,200 patent applications [14]

Core Insights - VILVI Group reported a consolidated sales revenue of EUR 215.8 million for the first nine months of 2025, reflecting an 18.9% increase compared to EUR 181.5 million in the same period of 2024 [1] - The Group's consolidated net profit for Q3 2025 was EUR 12.9 million, which represents a 35.2% decrease from EUR 19.9 million in Q3 2024 [1] Financial Performance - Consolidated sales revenue for the first nine months of 2025: EUR 215.8 million [1] - Year-over-year revenue growth: 18.9% [1] - Consolidated net profit for Q3 2025: EUR 12.9 million [1] - Year-over-year net profit decline: 35.2% [1]

Core Insights - Invalda INVL's equity reached EUR 222 million at the end of September, reflecting a year-over-year increase of 17.1% [1] - The company reported a net profit of EUR 13.9 million for the first nine months of 2025, down from EUR 25.8 million in the same period last year, attributed to lower investment returns [2] - The total value of client assets under management increased to EUR 2.08 billion, marking a 25.5% rise year-over-year [4] Financial Performance - Revenue from asset management for the first three quarters of 2025 was EUR 13.7 million, a 51.6% increase compared to the same period in 2024 [5] - The strategic business segment generated a profit of EUR 2.2 million, down from EUR 13.9 million in the previous year [5] Capital Raising and Investments - Invalda INVL successfully raised EUR 410 million for the INVL Private Equity Fund II, making it the largest private equity fund in the Baltics and one of the largest in Central and Eastern Europe [6] - The fund has completed two major acquisitions, including the largest waste management group in Estonia and a leading private healthcare services group in Poland [6] Equity Investments - The company earned EUR 13 million from equity investments in the first nine months of the year [7] - The performance of the equity investment portfolio was primarily driven by the banking sector and agricultural business, with significant contributions from Artea bank, Maib, and Litagra [8]

Core Points - FORVIA is undergoing a strategic review of its portfolio, leading to divestiture processes for parts of its Interiors business group [1] - The company emphasizes adherence to strict disclosure rules and governance standards, refraining from commenting on market rumors or specific confidential offers [2] - The current priority for FORVIA is to execute its roadmap with discipline while driving performance and empowering teams during its strategic transformation [2] Group 1 - FORVIA is engaged in selling parts of its robust portfolio as part of a comprehensive strategic review [1] - The divestiture processes are focused on assets within the Interiors business group [1] - The company is committed to maintaining transparency with employees, partners, and stakeholders regarding these processes [1] Group 2 - FORVIA does not disclose details on market rumors or specific offers, including valuation or pricing [2] - Any potential offers will require negotiation and approval from the Board of Directors [2] - The company aims to advance its strategic transformation while ensuring responsible execution of its plans [2]

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced the results of its Combined Shareholders' Meeting held on November 27, 2025 [1][10]. Voting Results - All resolutions submitted to the shareholders were adopted, except for resolution 5, which was negatively recommended by the Board of Directors. This resolution aimed to empower the Board to decide on share capital increases for a company savings plan [3][4]. - The Combined Shareholders' Meeting had a total of 441 shareholders represented, with a total of 119,608,674 votes cast, achieving a quorum of 56.432% [5]. - In the ordinary resolutions, the votes for resolutions ranged from 89.7% to 99.9% in favor, with the highest support for resolution 6 [6][7]. - In the extraordinary resolutions, resolution 4 was adopted with 89.9% in favor, while resolution 5 was rejected with only 41.6% support [8][9]. Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq, focusing on the research and development of oral small molecule therapies for MASH and other diseases with significant unmet medical needs. The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [10][11].

Core Insights - Michelin has initiated a securities repurchasing program, indicating a strategic move to enhance shareholder value through the buyback of ordinary shares [1][2] Group 1: Securities Repurchase Details - The repurchase program involves ordinary shares with the ISIN code FR001400AJ45 [1] - On November 28, 2025, Michelin acquired a total of 707,752 shares at an average price of 28.2585 euros per share [1] - The transactions were conducted over-the-counter, reflecting a direct approach to share buybacks [1] Group 2: Transaction Overview - The issuer's name is Michelin, with the issuer code being 549300SOSI58J6VIW052 [1] - The transaction was executed through BNP Paribas, indicating collaboration with a financial institution for the buyback process [1] - The total volume of shares acquired on the specified date highlights the company's commitment to returning capital to shareholders [1]

Core Insights - ZetaDisplay AB has published its Q3 Interim Report for January to September 2025, which is available on their investor relations website [1] - The company is a leader in the digital signage market, with over 125,000 active installations across more than 50 countries [4] Company Overview - Founded in 2003 in Sweden, ZetaDisplay is recognized as a pioneer in digital signage software and solutions [3] - The company operates in eight European countries and the US, providing comprehensive digital signage solutions to various sectors [4] - ZetaDisplay has a turnover exceeding SEK 600 million and employs approximately 250 staff members [5] Business Operations - The company offers a proprietary software platform, digital business development, consulting services, and innovative digital signage solutions [4] - ZetaDisplay serves a diverse clientele, including many respected blue-chip brands and companies [4] - The company is owned by Hanover Investors, an investment company [5]

The Supervisory Board of Eesti Energia has resolved, on the proposal of the Chairman of the Management Board, Andrus Durejko, to remove Management Board Member Kristjan Kuhi from the company’s Management Board. Kristjan Kuhi has served as a member of the Management Board since 1 April 2023, overseeing technology development and new business areas. His last working day at Eesti Energia will be 28 November 2025. From 2026 onwards, the Management Board of Eesti Energia will continue with four members, and the ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Galantas Gold Corporation (the ‘Company’) is pleased to announce its unaudited financial results for the Quarter ended September 30, 2025. Financial Highlights Highlights of the third quarter 2025 results, which are expressed in Canadian Dollars, are summarized below: All figures denominated in Canadian Dollars (CDN$)Quarter EndedSeptember 30 20252024Revenue$0 $0<td style="max-width:1%; width:1%; min-width:1%;;border-t ...

Core Insights - Zelluna has appointed Geir Christian Melen as the new Chief Financial Officer, effective January 1, 2026, succeeding Hans Vassgård Eid who will step down at the end of December 2025 [1][2][3] Company Overview - Zelluna ASA is a biotechnology company focused on developing allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for cancer treatment [4] - The company's lead program, ZI-MA4-1, targets the MAGE-A4 tumor antigen and is expected to enter clinical trials in 2026 [4] Leadership Transition - Geir Christian Melen has over seven years of experience with Zelluna as Finance Director and possesses a strong understanding of the company's TCR-NK platform and financial strategy [2][3] - The CEO of Zelluna, Namir Hassan, expressed appreciation for Hans Vassgård Eid's contributions, particularly in integrating Zelluna and Ultimovacs and preparing the company for clinical development [2]